Experienced in Hemorrhagic Proctocolitis

Nobuaki Nishimata

Kagoshima, JP 
Experienced in Hemorrhagic Proctocolitis
Kagoshima, JP 
OverviewLocationsClinical Research

Overview

Nobuaki Nishimata practices in Kagoshima, Japan. Nishimata is rated as an Experienced expert by MediFind in the treatment of Hemorrhagic Proctocolitis. Their top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Ulcerative Colitis, Hemorrhagic Proctocolitis, and Endoscopy.

Their clinical research consists of co-authoring 15 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles and participated in 1 clinical trial in the study of Hemorrhagic Proctocolitis.

Locations

Kagoshima, Japan
Other Locations
Chikushino-shi, 8188502, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: September 05, 2023
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
View 2 Less Clinical Trials

15 Total Publications

Induction Efficacy and Safety of Upadacitinib for Active Crohn's Disease in Japanese Patients: A Multicenter Retrospective Study.
Induction Efficacy and Safety of Upadacitinib for Active Crohn's Disease in Japanese Patients: A Multicenter Retrospective Study.
Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: May 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Nishimata's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile